Nosocomial pneumonia due to Acinetobacter baumannii;Neumonía nosocomial por Acinetobacter baumannii

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue SUPPL.3, 2005, Pages 46-51

  Cisneros Herreros, José Miguel ^a   Garnacho Montero, José ^a   Pachón Ibáñez, M Eugenia ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acinetobacter baumannii; Multiresistance; Nosocomial infection; Panresistance; Pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; COLISTIN; IMIPENEM; MEROPENEM; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TETRACYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; CLINICAL FEATURE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; MONOTHERAPY; NEPHROTOXICITY; PNEUMONIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CROSS INFECTION; DISEASE TRANSMISSION; DRUG EFFECT; MICROBIOLOGY; MULTIDRUG RESISTANCE; REVIEW;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL;

EID: 33749067622     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13091220     Document Type: Article

References (56)

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-65.
2. Allen DM, Hartman BJ. Acinetobacter species. En: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practices of infectious diseases. Phyladelphia: Elsevier INC.; 2005. p. 2632-6.
3. Rodríguez-Baño J, Cisneros JM, Fernández Cuenca F, Ribera A, Vila J, Pascual A, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in spanish hospital. Infect Control Hosp Epidemiol. 2004;25:819-24.
4. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis. 1993;167:448-51.
5. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerging Infect Dis. 2002;8:827-32.
6. Fernández F, Pascual A, Ribera A, Vila A, Bou G, Cisneros JM, et al. Diversidad clonal y sensibilidad a los antimicrobianos de Acinetobacter baumannii aislados en hospitales españoles. Estudio multicéntrico nacional: proyecto GEIH-Ab 2000. Enferm Infecc Microbiol Clin. 2004;22:267-71.
7. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel R, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States Hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000;31:690-7.
8. Cisneros JM, Rodríguez-Baño J, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, et al. Risk factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain. A nationwide study. [En prensa]. Clin Microbiol Infect. 2005.
9. Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a casecontrol study. Antimicrob. Agents Chemother. 2004;48:224-8.
10. Fierobe L, Lucet JC, Decré D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol. 2001;22:35-40.
11. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31:101-6.
12. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study of emerging antimicrobial resistence. Emerging Infect Dis. 2001;7:319-22.
13. Arroyo LA, Garcia-Curiel A, Pachón-Ibáñez ME, Llanos AC, Ruiz M, Pachón J, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005;43:903-5.
14. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites. Am J Resp Crit Care Med. 1999;160:608-13.
15. Troullet JL, Chastre J, Vaugnat A, Joly-Guillou L, Cambaux D, Dombert C, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Resp Crit Care Med. 1998;157:531-9.
16. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis. 1996;15:281-5.
17. Álvarez-Lerma F, Palomar-Martínez M, Olaechea-Astigarraga P, Insausti-Ordeñana J, Bermejo-Fraile B, Cerdá-Cerdá E. Estudio nacional de vigilancia de infección nosocomial en Unidades de Cuidados Intensivos. Informe del año 2002. Med Intensiva. 2005;29:1-12.
18. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, Marquez-Vacaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31:649-55.
19. Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by A. baumannii in intubated patients with pneumonia. Chest. 1997;112;1050-4.
20. Husni RN, Goldstein LS, Arroliga AC, Arroliga AC, Hall GS, Fatica C, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest. 1999;115:1378-82.
21. Garnacho-Montero J, Sole-Violan J, Sa-Borges M, Diaz-Santos E, Rello J. Clinical impact of pneumonia caused by A. baumannii in intubated patients: A matched cohort study. Crit Care Med. 2003;31:2478-82.
22. Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Dominguez MA, et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant A. baumannii. Clin Infect Dis. 1996;23:329-34.
23. García Garmendia JL, Ortiz Leyba C, Garnacho-Montero J, Jiménez Jiménez FJ, Pérez-Paredes C, Barrero- Almodóvar AE, et al. Risk factors for A. baumannii nosocomial bacteremia in critically ill patients: A cohort study. Clin Infect Dis. 2001;33:939-46.
24. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendía JL, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical and prognostic features. Clin Infect Dis. 1996;22:1026-32.
25. Husni RN, Goldstein LS, Arroliga AC, Arroliga AC, Hall GS, Fatica C, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest. 1999;115:1378-82.
26. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med. 1999;27:1794-9.
27. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis. 1996;23:538-42.
28. Rello J, Jubert P, Vallés J, Artigas A, Rue M, Niederman MS. Evaluation of outcome in intubated patients with pneumonia caused by Pseudomonas aeruginosa. Clin Infect Dis. 1996;23:973-8.
29. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Muñoz E, Sirgo G, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. [En prensa]. Crit Care Med. 2005.
30. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94:281-8.
31. Jordá J, Torres A, Ariza FJ, Alvarez F, Barcenilla F. Recomendaciones para el tratamiento de la neumonía intrahospitalaria grave. Documento de Consenso. Enferm Infecc Microbiol Clin. 2004;22:471-85.
32. Joly-Guillou ML, Wolf M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of A. baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother. 1997;41:345-51.
33. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-8.
34. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34:1425-30.
35. Rodríguez-Hernández MJ, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jimenez-Mejias ME, et al. J. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother. 2001;47:479-82.
36. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents. 2003;21:58-62.
37. Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect. 2005;11:24-30.
38. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect. 2002;8:687-93.
39. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, García-Curiel A, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother. 2000;45:493-501.
40. Bernabeu-Wittel M, Pichardo C, Garcia-Curiel A, Pachón- Ibáñez ME, Ibáñez-Martínez J, Jimenez-Mejias ME, et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect. 2005;11:319-25.
41. Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004;54:1085-91.
42. Rodríguez-Hernández MJ, Jimenez-Mejias ME, Pichardo C, Cuberos L, García-Curiel A, Pachón J. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. Clin Microbiol Infect. 2004;10:581-4.
43. Pachón-Ibáñez ME. Tratamiento de la neumonía experimental por Acinetobacter baumannii multirresistente y panresistente. Estudios de sinergia con carbapenemes, sulbactam, rifampicina y colistina in vitro e in vivo [tesis doctoral]. Universidad de Sevilla, 2005.
44. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglucosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant A. baumannii. Antimicrob Agents Chemother. 2002;46:1946-52.
45. Levin AS, Barone AA, Penço, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-11.
46. Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005;31:1058-65.
47. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibáñez-Martínez J, Garcia-Curiel A, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother. 2000;45:493-501.
48. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator- associated pneumonia. Intensive Care Med. 2003;29:2072-6.
49. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis. 2005;37:195-9.
50. Choi JY, Park YS, Cho CH, Park YS, Shin SY, Song YG, et al. Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii. Clin Microbiol Infect. 2004;10:1098-101.
51. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother. 2004;53:393-5.
52. Pachón-Ibánez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother. 2004;48:4479-81.
53. Dijkshoorn L, Brouwer CP, Bogaards SJ, Nemec A, Van den Broek PJ, Nibbering PH. The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004;48:4919-21.
54. Cisneros JM, Pachón J. Acinetobacter baumannii: un patógeno nosocomial de difícil control. Enferm Infecc Microbiol Clin. 2003;21:221-3.
55. Pimentel JD, Low J, Styles K, Harris OC, Hughes A, Athan E. Control of an outbreak of multi-drug-resistant Acinetobacter baumannii in an intensive care unit and a surgical ward. J Hosp Infect. 2005;59:249-53.
56. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis. 2003 15;36:1268-74.